Literature DB >> 17949279

Severe MDC1A congenital muscular dystrophy due to a splicing mutation in the LAMA2 gene resulting in exon skipping and significant decrease of mRNA level.

Olfa Siala1, Nacim Louhichi, Chahnez Triki, Madeleine Morinière, Ahmed Rebai, Pascale Richard, Pascale Guicheney, Faouzi Baklouti, Faiza Fakhfakh.   

Abstract

Congenital muscular dystrophies (CMDs) are a clinically and genetically heterogeneous group of neuromuscular disorders, with autosomal recessive inheritance. We report a patient with severe congenital muscular dystrophy and total deficiency in the laminin alpha2 chain. Genetic analyses showed a linkage to the MDC1A locus for the patient's family, and DNA sequencing revealed in the propositus of a new homozygous mutation in the donor splice site of intron 58 of the LAMA2 gene. RT-PCR experiments performed on total RNA from a patient's muscle biopsy showed a complete skipping of exon 58 in LAMA2 cDNA and a significant decrease in the LAMA2 mRNA level. This exon skipping altered the open reading frame of the mutant transcript and generated a premature termination codon (PTC) within exon 59, which potentially elicits the nonsense mRNA to degradation by NMD (nonsense-mediated mRNA decay). However, the residual exon 58-lacking mRNA could potentially be translated, and the resulting truncated alpha2 chain would lack its LG4 and LG5 domains that are involved in binding with alpha-dystroglycan. These results demonstrate the utility of mRNA analysis to understand the mutation primary impact and the disease phenotype in the patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17949279     DOI: 10.1089/gte.2006.0517

Source DB:  PubMed          Journal:  Genet Test        ISSN: 1090-6576


  1 in total

1.  Identification of Two Novel LAMA2 Mutations in a Chinese Patient with Congenital Muscular Dystrophy.

Authors:  Jing Zhou; Jianxin Tan; Dingyuan Ma; Jingjing Zhang; Jian Cheng; Chunyu Luo; Gang Liu; Yuguo Wang; Zhengfeng Xu
Journal:  Front Genet       Date:  2018-02-13       Impact factor: 4.599

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.